Beta-blocker drug abuse in the Huelva Province;Estudio de utilización de medicamentos betabloqueantes en la provincia de Huelva

Pharmaceutical Care Espana

Volumn 5, Issue 3, 2003, Pages 120-123

  Díaz Paradela, Manuel ^a   Díaz Mantis, Rafael ^a   Bravo Díaz, Luis ^b   Marhuenda Requena, Elisa ^b  

^a Bollullos Par del Condado   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

blockers; Dairy Defined Dose per 1000 residents and per day (DID)

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; GENERIC DRUG;

ARTICLE; CARDIOSELECTIVITY; CONTROLLED STUDY; DATA ANALYSIS; DRUG UTILIZATION; HEALTH CENTER; HUMAN; HYPERTENSION; MEDICAL RESEARCH; PRESCRIPTION; SPAIN;

EID: 0042377565     PISSN: 11396202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Molina Díaz R, et al. Hipertensión arterial en medicina de familia. Granada: Fundación Sociedad Andaluza de Medicina Familiar y Comunitaria. 1997
2. Ministerio de Sanidad y Consumo. Sociedad-Liga Española para la Lucha Contra la Hipertensión Arterial. Control de la hipertensión arterial en España, 1996. Madrid: IDEPSA, 1996.
3. Dustan HP. Controlling hypertension: a research success story. Arc Inten Med 1996; 156: 1926-1935.
4. Rangoonwala B, et al. Fixed dose combinations of ACE inhibitors. Br J Clin Pract 1996; 50: 454-65.
5. Gavras I, et al. Drug therapy for hypertension. Am Fam Physician 1997; 55: 1823-34.
6. Joint National Commitee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Commitee on Detection, Evaluation and Treatment of High Blood Pressure (JNCV). Arch Inter Med 1993; 153: 154-83.
7. OMS-ISH. The Guidelines Subcommittee of the WHO-ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the Management of Mild Hypertension. Memorandum from a World Health Organization-International Society of Hypertension Meeting. J Hypertens 1993; 11: 905-18.
8. Doughty R, et al. Effects of beta-blocker therapy on mortality in patients with hearth failure. Eur Heart J 1997; 18: 560-5.
9. Goodman y Gilman. Las bases farmacológicas de la terapéutica. Ed. McGraw-Hill-Interamericana. 9a ed. Madrid, 1996.
10. Díaz Paradela M, et al. Estudios de utilización de medicamentos: revisión. Pharm Care Esp 2000; 2: 3-7.
11. Díaz Paradela M, et al. Estudios de utilización de medicamentos hipolipemiantes en la provincia de Huelva. Pharm Care Esp 2002; 4: 31-40.
12. Valdés M, Tamargo J. Bloqueadores β-adrenérgicos en la hipertensión arterial y en la miocardiopatía hipertrófica. Medicine 1996; 7: 742-747.
13. Kaplan NM, et al. Choice of initial therapy for hypertension. JAMA 1996; 275: 1577-80.
14. Ministerio de Sanidad y Consumo. Grupos terapéuticos y Principios activos de mayor consumo en el Sistema Nacional de Salud durante 1997. Inf Ter Sist Nac Salud 1998;22:123-6.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N Eng J Med 1998; 339: 489-97.
16. McMenemy MC. β-blockers given the go-ahead for treatment of heart failure. Lancet 1998; 352:793.
17. Kaplan NM. Documentos de vanguardia en Hipertensión. Medical Trends. Barcelona, 1998.
18. Waagstein F. Beneficial effects of metoprolol in idiopatic dilated cardiomyopathy. Lancet 1993; 342: 1441-6.